



Company Overview

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.

Defining Next-Generation Allogeneic CAR T Development

Pursuing a Differentiated Strategy for CAR Ts



- All-in-One vector approach
- Proprietary allogeneic technologies
- shRNA – short hairpin RNA
- shARC franchise for armored CAR Ts
- TIM – TCR Inhibitory Molecule

shRNA and Allogeneic Equals Novel Approach



- Non-gene edited shRNA as a potential viable platform to develop allogeneic CAR Ts
- Able to multiplex by simultaneously knocking down multiple gene targets of interest
- Currently being evaluated in multiple clinical trials and preclinical studies

Robust Intellectual Property Estate



- Twelve foundational U.S. patents associated with allogeneic CAR T for the treatment of cancer
- Strong IP for NKG2D receptor-based cell therapies

A Differentiated Pipeline of Next Generation CAR T Candidates

Allogeneic

	TARGET	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	NEXT MILESTONES
CYAD-211	BCMA	r/r MM	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	• Additional data expected second half, 2022
CYAD-101	NKG2DL	mCRC	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	
DISCOVERY PROGRAMS			<div style="width: 100%; height: 10px; background-color: #800040;"></div>	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	<div style="width: 100%; height: 10px; background-color: #800040;"></div>	

Autologous

	TARGET	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	NEXT MILESTONES
CYAD-02	NKG2DL	r/r AML / MDS	<div style="width: 100%; height: 10px; background-color: #008080;"></div>	<div style="width: 100%; height: 10px; background-color: #008080;"></div>	<div style="width: 100%; height: 10px; background-color: #008080;"></div>	• Potential partnership opportunity

Company Financial Overview



Listed on:

Euronext & Nasdaq
CYAD

Market Capitalization:

~ €33,56 M

Cash Balance*:

€ 20.5 million

*(all figures reported as of March 31, 2022)

Leadership



Filippo Petti
CEO / CFO



Charles Morris
CMO



David Gilham
CSO



Philippe Dechamps
CLO



Frédéric Lehmann
VP Clinical Dev.
& Med. Affairs



Philippe Nobels
VP Human Resources

Upcoming Milestones

❑ CYAD-211 in r/r MM

Enrollment in the cohorts evaluating enhanced lymphodepletion is ongoing in the CYAD-211 IMMUNICY-1 trial and additional data from the trial are expected in the second half of 2022

❑ shARC Franchise

Exploration continues for allogeneic NKG2D receptor CAR T candidates currently in the discovery stage that leverage the shARC platform.

Partnerships

Since its incorporation, Celyad Oncology has built strong partnerships with key international academic institutions and strategic organizations in order to maximize the therapeutic potential of its product candidates and intellectual property.

Our Partners:

- Celdara Medical
- Dartmouth College
- Horizon Discovery
- MSD
- Novartis
- Walloon Region of Belgium



Locations

Headquarters:

Axis Business Park
Rue Edouard Belin 2,
1450 Mont-Saint-Guibert

Belgium

World Financial District
60 Broad Street | Suite 3502
New York, NY 10004

USA



Contacts

+32 (0) 10 39 41 00
+1 (857) 990-6900

info@celyad.com